Using HDAC3 Inhibitors to Reverse CREBBP Mutations in Lymphomas

This research could potentially pave the way for possible immunotherapy approaches for common forms of non-Hodgkin lymphoma.

Source: CancerNetwork - January 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news